

FDA CONFLICT OF INTEREST WAIVERS

Dr. Scher advised the FDA that he has a financial interest related to the above topic that could potentially be affected by his participation [REDACTED]. Dr. Scher reported that he has joint stock a current value of [REDACTED]. Additionally he reported that his institution has a grant from (c o m p e t i n g f m) . The grant is current and his institution receives per year from 2006-2007. Dr. Scher receives no salary [REDACTED]. The grant is to study a licensed, approved drug (In pro) state cancer trials. [REDACTED] is a licensed drug currently used in other cancer therapies. Dr. Scher also reported that his institution has [REDACTED] n p e t i n g f r m). The [REDACTED] and his institution r e c e i v e s p e r year from 2006-2008. Dr. Scher receives no salary from the [REDACTED] n i n v e s t i g a t i o n a l d r u g m t h a t is also being studied in several types of cancer. It is unlikely that Dr. Scher's participation in the discussions on March 29 of a cellular therapy for prostate cancer will have a direct and predictable [REDACTED] on his financial [REDACTED].

Dr. Maha Hussain advised the FDA that she has a financial interest related to the above topic that could potentially be affected by her participation [REDACTED]. Dr. Hussain [REDACTED] that her husband owns stock in the following competing firms: - - - PDr. Hussain [REDACTED] does not hold control in the purchase or sale of the stocks. Dr. Hussain also is the principal investigator on an unrelated research contract [REDACTED] a competing firm. Dr. [REDACTED] institution receives approximately per year from May 2006 to September 2009. She does [REDACTED] personal remuneration [REDACTED] research contract does not entail a direct and predictable affect on the interest.

www.CareToLive.com